Because inhibition of NFκB counteracts cytoprotection by IL-4, and is associated to an attenuated response of a set of IL-4 targets, NFκB targeting should be further explored especially in CLL patients expressing bad prognostic markers. Here, IL4 is linked to B-cell chronic lymphocytic leukemia.